Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-036831
Filing Date
2025-03-11
Accepted
2025-03-11 07:37:57
Documents
96
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K achv-20241231.htm   iXBRL 10-K 3987469
2 EX-10.19 achv-ex10_19.htm EX-10.19 113094
3 EX-10.36 achv-ex10_36.htm EX-10.36 113440
4 EX-19.1 achv-ex19_1.htm EX-19.1 99754
5 EX-21.1 achv-ex21_1.htm EX-21.1 3304
6 EX-23.1 achv-ex23_1.htm EX-23.1 3428
7 EX-31.1 achv-ex31_1.htm EX-31.1 12098
8 EX-31.2 achv-ex31_2.htm EX-31.2 15347
9 EX-32.1 achv-ex32_1.htm EX-32.1 5761
10 EX-32.2 achv-ex32_2.htm EX-32.2 6187
11 GRAPHIC img25712573_0.jpg GRAPHIC 43607
  Complete submission text file 0000950170-25-036831.txt   15226098

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20241231.xsd EX-101.SCH 1870793
99 EXTRACTED XBRL INSTANCE DOCUMENT achv-20241231_htm.xml XML 2801113
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 033-80623 | Film No.: 25725869
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)